Brought to you by 
Lilly shares in development costs and profits for Pfizer’s troubled tanezumab; deal ends
25 Jul 2022
Executive Summary
As Pfizer Inc. attempts to get its Phase III pain compound tanezumab out of a partial clinical hold, the company finds a new partner in Eli Lilly & Co., which agreed to share in the development costs and profits of the project.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly shares in development costs and profits for Pfizer’s troubled tanezumab; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice